Otologic Pharmaceutics is a development-stage biopharmaceutical company based in Oklahoma City focused on developing and commercializing novel pharmacological approaches to treat hearing disorders. Its lead product candidate is referenced as NHPN-1010, and the article also identifies HPN1010 as an oral treatment for Acute Hearing Loss. The company plans to advance its lead candidate into clinical development, with HPN1010 scheduled to enter clinical trials in 2014. Otologic intends to use the proceeds from its recent financing to advance development of NHPN-1010. The company underwent executive leadership change in conjunction with the financing: Clayton I. Duncan of Accele Biopharma was named CEO, replacing David Karlman. No operating metrics (revenue/users) were disclosed in the article. Otologic Pharmaceutics is a development-stage pharmaceutical company based in Oklahoma City focused on commercializing novel pharmacological solutions for hearing health. Its core work centers on advancing therapeutics for inner ear disorders and other hearing-health applications. The company has in-licensed a portfolio of 19 patents that underpin its programs. A team of nationally and internationally recognized inner ear medicine experts, biomedical research scientists and business leaders supports its development and commercialization efforts. Otologic recently closed a financing round of undisclosed amount led by the OCAST Technology Business Finance Program with participation from INTEGRIS Health and the Oklahoma Medical Foundation. The company says the funding will enable it to advance its therapeutics and continue building the business.

Total raised

$4M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2014